SCHEMBL796948

SCHEMBL796948

O=[N+]([O-])c1cnc2ccc(Cl)nc2c1O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.43
KDM4E B2RXH2 4/20 0.43
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
TDP1 Q9NUW8 4/20 0.43
PKM P14618 3/20 0.43
L3MBTL1 Q9Y468 3/20 0.43
HTT P42858 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
LMNA P02545 2/20 0.43
ALDH1A1 P00352 3/20 0.40
GPR35 Q9HC97 2/20 0.40
CTSB P07858 2/20 0.40
IDO1 P14902 2/20 0.40
TDO2 P48775 2/20 0.40
GAA P10253 1/20 0.40
HSP90AA1 P07900 1/20 0.40
OPRK1 P41145 1/20 0.40
GRIN2D O15399 1/20 0.39
GRIN3B O60391 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL796918 0.84 TXNRD1 (0.39) MAPTTDP1L3MBTL1POLBTXNRD1
SCHEMBL16748191 0.82 MAPT (0.40) MAPTTDP1L3MBTL1ALDH1A1POLB
SCHEMBL15174711 0.78 ERN1 (0.47) MAPTMEN1KMT2AHTTHSP90AA1
SCHEMBL30428949 0.75 GPR35 (0.41) MAPTKDM4EMEN1KMT2ATDP1
SCHEMBL191920 0.75 MAPT (0.60) MAPTKDM4EMEN1KMT2ATDP1
SCHEMBL23878654 0.74 MERTK (0.40) MAPTMEN1KMT2AHTTPIN1
SCHEMBL404980 0.73 TSHR (0.45) MAPTKDM4EMEN1KMT2ATDP1
SCHEMBL14905211 0.72 EGFR (0.38) KDM4EMEN1KMT2ATDP1HTT
SCHEMBL808254 0.72 MELK (0.33) MAPTKDM4ETDP1L3MBTL1ALDH1A1
SCHEMBL29810194 0.72 MELK (0.42) MAPTKDM4EMEN1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3072893-B1 KETONE DERIVATIVES OF IMIDAZOLES, PHARMACEUTICAL COMBINATIONS AND USES THEREOF BEIJING FORELANDPHARMA CO LTD (CN) 2020-03-18 EP disclosed
EP-3072893-B1 KETONE DERIVATIVES OF IMIDAZOLES, PHARMACEUTICAL COMBINATIONS AND USES THEREOF BEIJING FORELANDPHARMA CO LTD (CN) 2020-03-18 EP disclosed
US-20170283429-A1 COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS Janssen Biopharma, Inc. 2017-10-05 US disclosed
US-20170283429-A1 COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS Janssen Biopharma, Inc. 2017-10-05 US disclosed
US-9724351-B2 Compounds for the treatment of paramoxyvirus viral infections ALIOS BIOPHARMA, INC. (US) 2017-08-08 US disclosed
US-9724351-B2 Compounds for the treatment of paramoxyvirus viral infections ALIOS BIOPHARMA, INC. (US) 2017-08-08 US disclosed
CN-104447740-B Imidazolone derivative as well as drug composition and application thereof 北京富龙康泰生物技术有限公司 2017-02-22 CN disclosed
CN-104411706-B Imidazolone derivatives, pharmaceutical compositions and uses thereof 北京富龙康泰生物技术有限公司 2016-11-16 CN disclosed
US-20160304510-A1 IMIDAZOLONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BEIJING FORELANDPHARMA CO. LTD. (CN) 2016-10-20 US disclosed
US-20160304510-A1 IMIDAZOLONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BEIJING FORELANDPHARMA CO. LTD. (CN) 2016-10-20 US disclosed
WO-2015074516-A1 KETONE DERIVATIVES OF IMIDAZOLES, PHARMACEUTICAL COMBINATIONS AND USES THEREOF 北京富龙康泰生物技术有限公司 2015-05-28 WO disclosed
CN-104447740-A Imidazolone derivative as well as drug composition and application thereof BEIJING FORELAND BIOPHARMA CO LTD 2015-03-25 CN disclosed
WO-2014079364-A1 IMIDAZOLONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF 北京富龙康泰生物技术有限公司 (CN) 2014-05-30 WO disclosed
US-20130190307-A1 FUSED HETEROARYLS AND THEIR USES HUTCHISON MEDIPHARMA LIMITED (CN) 2013-07-25 US disclosed
US-20130190307-A1 FUSED HETEROARYLS AND THEIR USES HUTCHISON MEDIPHARMA LIMITED (CN) 2013-07-25 US disclosed
US-20130190307-A1 FUSED HETEROARYLS AND THEIR USES HUTCHISON MEDIPHARMA LIMITED (CN) 2013-07-25 US disclosed
EP-2616468-A1 FUSED HETEROARYLS AND THEIR USES Hutchison Medipharma Limited (CN) 2013-07-24 EP disclosed
CN-102399218-A Triheterocyclic compounds and their use as PI3K inhibitors HUTCHISON MEDIPHARMA LTD 2012-04-04 CN disclosed
WO-2012034526-A1 FUSED HETEROARYLS AND THEIR USES HUTCHISON MEDIPHARMA LIMITED (CN) 2012-03-22 WO disclosed
WO-2012034526-A1 FUSED HETEROARYLS AND THEIR USES HUTCHISON MEDIPHARMA LIMITED (CN) 2012-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160304510-A1 IMIDAZOLONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DMPK, MAP3K15, MAP4K2 MAPT 2230/4885KDM4E 3065/4885MEN1 1190/4885
US-20170283429-A1 COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS MAVS, SARS1, ZC3HAV1 MAPT 4377/4885KDM4E 3430/4885MEN1 4770/4885
US-20130190307-A1 FUSED HETEROARYLS AND THEIR USES FARS2, TIAL1, DHFR MAPT 2577/4885KDM4E 4268/4885MEN1 1459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.